NATCO is an Indian pharmaceutical company that manufactures and markets various pharmaceutical drugs, healthcare products, and chemical formulations. The company also provides chemical manufacturing services on a contract basis. NATCO is headquartered in Hyderabad. In addition to India, NATCO has operations in Canada, Australia, the Philippines, Brazil, and other countries. The company is known as a major producer of cancer-related medicines and drugs for treating Hepatitis-C.
On 19 December 2022, the market capitalisation of the company was Rs 10,041.56 crore. It reported consolidated sales of Rs 351.1 crore at the end of September 2022. The company is listed on the Bombay Stock Exchange with the code 524816 and the National Stock Exchange with the code NATCOPHARM.
On 30 September 2022, the company’s shareholding pattern indicated a promoter stake of 48.8%, a 0% stake of foreign institutional investors, and DIIs held a stake of 14.3%, and the public held a stake of 36.9% in the company. The company’s shareholding pattern has remained largely consistent over the past year, with the exception that the FII stake in the company has gone down from around 20% to nil.
The company’s board of directors comprises GS Murthy, VC Nannapenni, Rajeev Nannapenni, P S R K Prasad, D G Sharaf, Leela Digumarti, MUR Naidu, and T V Rao, Pavan Bhatt, and others. The auditors are B S R & Associates LLP. On 30 September 2022, the company had a total of 18.26 crore shares outstanding.
On 19 December 2022, NATCO Ltd.’s share price on BSE was Rs 550.10 and Rs 550 on NSE. The share price touched a 52-week high of Rs 944 and a 52-week low of Rs 545. Its three-month return to investors was -13.56%, while its one-year return was -34.8%.
As of November 2022, Mirae Asset Emerging Bluechip Direct-Growth had invested Rs 207.7 crore in the company, while ICICI Pru Value Discovery Direct-G and Mirae Asset Midcap Fund Direct-G had invested Rs 163.9 and Rs 116.6 crore, respectively.
The company’s peers include Ajanta Pharma, Suven Pharma, and Glenmark Pharma.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.
Invest
FAQ’s on Natco Pharma Ltd Shares
